Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
May 08, 2026 20:45 ET | Source: Amplia Therapuetics Limited Melbourne, Australia,…
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
April 07, 2026 08:05 ET | Source: NextCure The U.S. Food and…
Biosplice Therapeutics Announces First Patient Dosed in InvestigatorInitiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD PlatinumResistant Ovarian Cancer
SAN DIEGO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”),…
